COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work

Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work

STOUGHTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journal’s 2020 Best Places to Work.

“We are honored to be recognized by the Boston Business Journal, and importantly, by our employees, as one of Boston’s best places to work,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “At Collegium, we are fortunate to have a remarkably talented team of people who are committed to upholding our core values and dedicated to our mission of becoming the leader in responsible pain management.”

The Boston Business Journal’s Best Places to Work program recognizes companies that have built extraordinary work environments for their people. This year, Boston Business Journal recognized companies ranging in size and industry. The rankings are determined by employees’ responses to survey questions which focus on work environment, work-life balance, job satisfaction, advancement opportunities, management, compensation and benefits.

For more information on career opportunities at Collegium, and to learn more about our mission and core values, please visit the careers portion of our company website at .

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the company’s website at .

Contact:

Alex Dasalla

EN
17/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 11,659 shares at 34.363USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

 PRESS RELEASE

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 O...

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to...

 PRESS RELEASE

Collegium to Report Second Quarter 2025 Financial Results on August 7,...

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2025 Earnings Call.” An audio webc...

 PRESS RELEASE

Collegium Announces $150 Million Share Repurchase Program

Collegium Announces $150 Million Share Repurchase Program STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026. This program replaces a previous $150 million share repurchase program authorized in January 2024 which expired on June 30, 2025, and had $65 million remaining under the progr...

 PRESS RELEASE

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare ConferencePresentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch